Peter A. Crooks Institution Verified

Sourced from institutional research profiles (UAMS TRI or ARA).

◆ ARA Academy High Impact

Drug research

University of Arkansas for Medical Sciences

faculty

57 h-index 925 pubs 14,766 cited

Research Areas

Links

ORCID Google Scholar Research Group UAMS TRI Profile

Edit your profile

OverviewAI-generated summary

Peter A. Crooks is a distinguished researcher with over forty years of experience in drug design and discovery, focusing significantly on cancer-related research since the 1980s. His extensive work has resulted in over 560 publications in medicinal chemistry and drug synthesis, alongside more than 100 patents in drug discovery. Crooks is recognized internationally for his expertise in prodrug and codrug design, drug metabolism, and pharmacokinetics, all critical areas for preclinical drug development. He has demonstrated a strong entrepreneurial spirit, founding seven drug discovery start-up companies, and several of his discoveries have progressed to clinical trials. Notably, his anticancer drug Valchlor® has received FDA approval for treating cutaneous T-cell lymphoma, with other drug candidates currently in Phase 1 and later-stage clinical development.

His research group is actively involved in investigating novel therapeutic agents for various diseases. Recent publications highlight work on precision medicine models for glioblastoma, the development of anticholinesterase therapeutics for Alzheimer's disease, and understanding the mechanisms of ferroptosis in hepatocellular carcinoma. Further research explores the therapeutic potential of antihypertensive agents against drug-induced cardiotoxicity and the antitumor properties of sesquiterpene lactone analogs as NFκB inhibitors. Crooks' scholarship is reflected in his h-index of 57, over 925 total publications, and more than 14,700 citations, underscoring his significant contributions to the field. He is an ARA Academy member and has been identified as a high-impact researcher.

Metrics

h-index: 57
Publications: 925
Citations: 14,766

Selected Publications

Vesicular monoamine transporter-2 inhibitor JPC-141 prevents methamphetamine-induced dopamine toxicity and blocks methamphetamine self-administration in rats (2024) DOI
Thiadiazolidinone (TDZD) Analogs Inhibit Aggregation-Mediated Pathology in Diverse Neurodegeneration Models, and Extend C. elegans Life- and Healthspan (2023) DOI
High flux novel polymeric membrane for renal applications (2023) DOI
Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in rats (2023) DOI
Parthenolide induces rapid thiol oxidation that leads to ferroptosis in hepatocellular carcinoma cells (2022) DOI
Characterizing the Access of Cholinergic Antagonists to Efferent Synapses in the Inner Ear (2021) DOI
Biobanked Glioblastoma Patient-Derived Organoids as a Precision Medicine Model to Study Inhibition of Invasion (2021) DOI
Novel hydroxybenzylamine-deoxyvasicinone hybrids as anticholinesterase therapeutics for Alzheimer’s disease (2021) DOI
Antitumor properties of novel sesquiterpene lactone analogs as NFκB inhibitors that bind to the IKKβ ubiquitin-like domain (ULD) (2021) DOI
Therapeutic Potentials of Selected Antihypertensive Agents and Their Fixed-Dose Combinations Against Trastuzumab-Mediated Cardiotoxicity (2021) DOI
Evaluation of bone and kidney toxicity of BT2-peg2, a potential carrier for the targeted delivery of antibiotics to bone (2021) DOI
A pharmacokinetic study of <scp>morphine‐6‐<i>O</i></scp>‐sulfate in rat plasma and brain (2021) DOI